Obesity or Overweight Clinical Trial
Official title:
Efficacy and Safety of Cagrilintide S.C. 2.4 mg in Combination With Semaglutide S.C. 2.4 mg (CagriSema S.C. 2.4 mg/2.4 mg) Once-Weekly in East Asian Participants With Overweight or Obesity
This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1½ years.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03629301 -
Obesity Treatment Using an Internet-delivered Intervention Based on the Diabetes Prevention Program in Mexican Adults
|
N/A | |
| Active, not recruiting |
NCT05607680 -
A Study of IBI362 in Participants With Obesity or Overweight
|
Phase 3 | |
| Completed |
NCT05153590 -
A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
|
||
| Recruiting |
NCT05996848 -
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
|
Phase 3 |